Why Economics, Not Science, Is Failing Drug Discovery

How could dual-targeting therapies reshape outcomes for patients with relapsed myeloma?

A new clinical trial has delivered major progression-free survival gains by simultaneously hitting two key targets, offering fresh hope in a hard-to-treat setting.

Explore the trial results and what they mean for future treatment strategies.
#SyenzaNews #oncology #clinicaltrials #innovation

✨ What weight reductions are retatrutide’s Phase 3 results showing?

New trial data highlights meaningful efficacy signals that could reshape obesity management and accelerate pharmaceutical innovation.

Explore the full implications for drug development and market access.
#SyenzaNews #clinicaltrials #pharmaceuticals #innovation

🚀 Can regulatory reforms unlock Europe’s biotech edge?

Streamlined approvals and reduced bureaucracy are at the heart of new EU proposals designed to attract investment and speed up innovation.

See what these changes could mean for the sector.

#SyenzaNews #biotechnology #regulatoryaffairs #innovation #MarketAccess

How can Health Technology Assessment reshape funding for social care?

Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems.

Read the full piece to see how these strategies are driving meaningful change.

#SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation

👁️ Can a photovoltaic implant restore functional vision for AMD patients?

A new subretinal photovoltaic implant is demonstrating the ability to safely restore meaningful sight in people with advanced age-related macular degeneration, offering fresh hope where traditional treatments fall short.

Discover how this device is advancing retinal prosthetics.
#SyenzaNews #medicaldevices #biotech #innovation

🚀 What’s next for robotic surgery in the OR?

A new table-integrated robotic surgery system has received FDA authorization, enabling seamless workflow, enhanced precision, and greater efficiency during minimally invasive procedures.

Learn how this milestone could reshape surgical practice.
#SyenzaNews #MedTech #medicaldevices #innovation

💊 How are phased tariffs set to transform generic drug supply chains?

New policies using gradual tariff adjustments are incentivizing manufacturers to reshore production, boosting domestic output and enhancing resilience in pharmaceuticals.

Explore the economic and strategic implications for global drug markets.
#SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #innovation

How is CMS reshaping coverage for digital therapeutics in chronic care?

The new model aims to expand access to digital therapeutics and connected devices, helping providers deliver more effective, tech-enabled support for chronic conditions.

Discover what this means for payers, innovators, and patients.

#SyenzaNews #digitalhealth #HealthcareInnovation #innovation #DigitalTransformation

How is South Africa advancing access to next-generation treatments for diabetes and obesity?

Novo Nordisk, through its partnership with Extensior, has secured authorization to release semaglutide, expanding options for patients across the country.

Explore what this approval means for local healthcare delivery and market access.
#SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #innovation

💊 Could once-weekly dosing redefine HIV treatment adherence?

A new trial confirms that islatravir combined with lenacapavir delivers sustained viral suppression, offering a promising step toward simpler, longer-acting regimens for people living with HIV.

Read the full analysis and implications for drug development.
#SyenzaNews #clinicaltrials #pharmaceuticals #innovation